ER-alpha 36, A Novel Biomarker for ER-Negative Breast CancerYang Wang1 and Wei Zou2,3*
- *Corresponding Author:
- Yang Wang
Department of Medical Microbiology and Immunology
Creighton University, Omaha, USA
E-mail: [email protected]
Received date September 21, 2016; Accepted date September 21, 2016; Published date September 28, 2016
Citation: Wang Y, Zou W (2016) ER-α36, A Novel Biomarker for ER-Negative Breast Cancer. Mol Biol 5:e138. doi:10.4172/2168-9547.1000e138
Copyright: © 2016 Wang Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Breast cancer is one of the most common cancers among women in the world. The expression level of estrogen receptor-alpha (ER-α) is an important diagnostic factors for breast cancer. ER-α is a 66 kDa, ligand-induced transcription factor . Tamoxifen has been proven as a successful treatment for ER-positive breast cancer for decades; however some breast tumors are finally resistant to tamoxifen therapy. The molecular mechanisms underlying tamoxifen resistance is still largely unknown.